首页> 外文OA文献 >Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

【2h】

Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

机译：回复剂量调整的流管环磷酰胺，多柔比星，长春螯合物和泼尼松化疗的活性和安全性，在非常老年患者中患者缺乏预后未经治疗的差异大B细胞非霍奇金淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Antonino Musolino; Daniela Boggiani; Michele Panebianco;
展开▼
作者单位

展开▼
年度 2011
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. [J] . Musolino A, Boggiani D, Panebianco M Cancer: A Journal of the American Cancer Society . 2011,第15期

机译：对年纪大，预后差，未经治疗的弥漫性大B细胞非霍奇金淋巴瘤的老年患者进行剂量调整后的输注环磷酰胺，阿霉素，长春新碱和泼尼松化疗联合利妥昔单抗的活性和安全性的答复。
2. Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma [J] . Antonino Musolino MD PhD Daniela Boggiani MD Michele Panebianco MD Cancer . 2011,第15期

机译：对年纪大，预后差，未经治疗的弥漫性大B细胞非霍奇金淋巴瘤预后很差的老年患者进行剂量调整的输注环磷酰胺，阿霉素，长春新碱和泼尼松化疗联合利妥昔单抗的活动性和安全性的答复
3. Erratum: Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma (Cancer (2011) 117 (3530)) [J] . Noauthornameavailable Cancer: A Journal of the American Cancer Society . 2012,第13期

机译：勘误：调整后剂量的输注环磷酰胺，阿霉素，长春新碱和泼尼松化疗联合利妥昔单抗治疗极年长预后差的未治疗弥漫性大B细胞非霍奇金淋巴瘤的患者（Cancer（2011）117（3530））
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab Etoposide Prednisone Vincristine Cyclophosphamide Doxorubicin) Chemotherapy Regimen [O] . Anahat Kaur, Omar Abughanimeh, Yousaf Zafar, -1

机译：弥漫性大B细胞淋巴瘤表现为双侧肾脏包块：用剂量调整的REPOCH（利妥昔单抗依托泊苷泼尼松长春新碱环磷酰胺阿霉素）成功治疗
6. Erratum: Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma [O] . 2011

机译：错误的：在非常贫困的未经治疗的未处理弥漫性大型B细胞非霍格金淋巴瘤中，用Rituximab患者的剂量调整的流管环磷酰胺，多柔比蛋白，长春新碱和泼尼松化疗的活动和安全性

Reply to activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅